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Background: Inflammatory bowel diseases (IBD) are a growing global health problem. 
Current pharmacological therapies are not effective in all IBD patients, tend to cause side 
effects and in some cases lose effectiveness when used for a prolonged period of time. 
Hence, there is a need to develop dietary interventions that are safe and be applicable to all. 
Chronic inflammation of the gut could be combated by increasing the consumption of dietary 
fiber which would lead to an increased butyrate production in the colon. Butyrate has been 
shown to improve intestinal integrity and suppress the secretion of pro-inflammatory 
cytokine, IL-8 – which is commonly found at high concentrations in IBD patients. 
Hypothesis: When inflamed human intestinal cells (Caco-2) are exposed to an increased 
ratio of butyrate to physiological concentrations of acetate and propionate, the intestinal 
integrity would be improved and the secretion of IL-8 would be suppressed.  
Experimental Design: Caco-2 cells were grown to 90-100% confluence on Transwell plate 
inserts for 4 days. Then, inflammation was induced for 24h. The inflamed and non-inflamed 
Caco-2 cells were then exposed to: (i) 60 mM acetate (Ac): 10mM propionate (Pr): 10mM 
butyrate(Bu) (lower butyrate ratio) or (ii) 60 mM Ac: 10mM Pr: 20mM Bu (higher butyrate 
ratio)  for 0h, 12h or 24h. Intestinal integrity was measured by amount of Lucifer yellow 
transported from the apical to basolateral chamber of Transwell plates. IL-8 secretion was 
measured by ELISA and cell damage was measured by the lactate dehydrogenase 
cytotoxicity assay. 
Results: Cells that were inflamed significantly decreased the intestinal integrity (p=0.0094), 
increased the secretion of IL-8 (p<0.0001) and induced higher cell damage (p<0.0001) than 
non-inflamed Caco-2 cells, n=54. SCFA mix containing higher butyrate ratio (20mM) 




significantly reduced the intestinal integrity of inflamed cells (p=0.0238, n=27). Higher 
butyrate ratio did not affect the secretion of IL-8; but it led to greater cell-damage (p=0.0161, 
n=54). Prolonged exposure to SCFA improved intestinal integrity (p<0.0001), increased the 
secretion of IL-8 (p<0.0001) and led to greater cell damage (p<0.0001), n=36.  
Conclusion: Our hypothesis was disproved. But the important lesson to be learned is that the 
effect of butyrate in colonocyte models should be studied in the presence of other SCFA, to 
assure physiological relevance. 




CHAPTER 1: GENERAL INTRODUCTION 
 
INFLAMMATORY BOWEL DISEASES (IBD) 
What is IBD and its burden on society? 
Chronic inflammation of the large intestine leads to development of inflammatory bowel 
disease (IBD). There are two kinds of IBD, namely, Ulcerative Colitis (UC) and Crohn’s 
Disease (CD). According to Centers for Disease Control and Prevention (CDC), 1 – 1.3 
million people suffer from IBD in USA. Although the prevalence of IBD is higher in the 
developed nations, the incidence and prevalence of IBD is growing in the developing nations 
as well (Molodecky et al., 2012). USA spends more than $6 billion in direct medical costs 
associated with IBD (Kaplan, 2015a). With the growing incidence rate in developing and 
developed nations, the direct and indirect medical cost is only going to increase, making IBD 
a global health problem that needs attention. 
Which factors contribute towards development of IBD? 
The pathogenesis of IBD is attributed to the complex interaction between genetics, 
environment, gut microbes and the immune system. With the advent of inexpensive ways of 
DNA sequencing, it has become easier to find the genes that might be associated with IBD or 
other diseases. Henderson and Satsangi (Henderson & Satsangi, 2011) have neatly 
summarized the genes and pathways that have been implicated in the etiology of IBD, as 
shown in Fig. 1.  
 





Fig.1. Broad overview of the genetic architecture of inflammatory bowel disease giving 
examples of confirmed and candidate genes implicated in each pathway. Treg - regulatory T 
cell. (Adapted from Henderson & Satsangi, 2011). 
 
Several environmental factors have been shown to be associated with the risk of IBD. For 
example, consuming fruits and vegetables that is rich in dietary fiber is associated with 
decreased risk of developing both UC and CD (Molodecky & Kaplan, 2010; 
Ananthakrishnan, 2013). Similarly, cigarette smoking, appendectomy, psychosocial stress, 
depression, use of non-steroidal anti-inflammatory drugs (NSAID), dietary animal protein 
and usage of contraceptive pills have been associated with increasing the risk of developing 
CD; and on the other hand, consumption of vitamin D and dietary fiber have been associated 
with decreasing the risk of developing CD (Molodecky & Kaplan, 2010; Ananthakrishnan, 
2013). The factors that increase the risk of developing UC are dietary arachidonic acid and 
linoleic acid, usage of NSAID, psychosocial stress, depression  and post-menopausal 
hormonal use; and the factors that decrease the risk of developing UC are cigarette smoking, 




appendectomy and dietary n-3 fatty acids (Molodecky & Kaplan, 2010; Ananthakrishnan, 
2013). 
The role of the immune system in developing IBD has been studied extensively (De Souza & 
Fiocchi, 2016). The gut microbiota plays an important role in the development of host 
immune system. Due to this connection between the immune system and the gut microbiota, 
it is safe to presume that the gut microbiota may play a role in pathogenesis of IBD.  
Joossens et al. determined that when the fecal microbial composition of patients with CD 
was compared with that of their unaffected relatives, there was a significant decrease in the 
commensal bacteria like Firmicutes and increase in pathogenic ones like Escherichia coli 
(E.coli) (Joossens et al., 2011). Similar such studies (Andoh et al., 2011; Gong et al., 2016) 
have found reduced microbial diversity and microbial composition are involved in the 
development of IBD – suggesting that the microbial composition could be manipulated to 
improve the effects of IBD. 
In a nutshell, IBD is a growing global health problem. Genetic, environmental, 
immunological and gut microbial factors contribute towards the development of IBD. These 
factors could be targeted and modulated to develop effective strategies to prevent and cure 
IBD. 
What can be done to prevent or treat IBD? 
Disruption of the delicate equilibrium between the luminal microbial flora, intestinal 
epithelium and the immune system leads to inflammation of the gut. If the immune system 
becomes over-active, chronic inflammation persists that result into development of IBD. 
Hence, altering the microbial flora, improving the intestinal epithelial barrier function or 
targeting the immune system may be effective in treating or preventing IBD.  




Caballero-Franco et al. determined the effect of a probiotic mixture, VSL#3, containing 
species from Lactobacillus, Bifidobacteria and Streptococcus genera on the mucus layer 
protein (mucin) secretion and expression of mucin secretion genes in 4-6 weeks old Wistar 
rats. The rats were fed 0.15 mg/kg (3 x 10
9
 bacteria) of live VSL#3 probiotic formula 
dissolved phosphate-buffered saline (PBS) or PBS alone as a negative control, 
intragastrically for 7 days. VSL#3 treatment led to a 5-fold increase in the expression of 
mucin secretion gene, MUC2 and concomitantly, 60% increase in mucin secretion in the rat 
colons, in comparison with the control rat colons (Caballero-Franco et al., 2007). This 
indicates how addition of beneficial microbes to the gut led to an improvement in 
development of the mucus layer which is the first line of defense for the gut. 
In a randomized, placebo-controlled, cross-over study, Karczewski et al. determined the 
effect of duodenal administration of 10
12
 cells of Lactobacillus plantarum (L.plantarum) 
strain WCFS1or placebo for 6h on secretion of tight junction proteins – zonula 
occludens(ZO)-1 and occluding (OC), in healthy volunteers (n =7). Tissue biopsies were 
obtained after each treatment by gastroduodenoscopy and then stained to be analyzed by 
using the confocal laser scanning microscopy. They found that the tissues obtained from the 
volunteers when L. plantarum was administerd, were significantly highly stained for OC and 
ZO-1 when compared with tissues obtained from the volunteers during the placebo treatment. 
The researchers also determined the effect of 100 colony forming units (cfu) L.plantarum on 
tight junction proteins and permeability of Caco-2 BBe cell monolayers. They found that 
Caco-2 cells treated with L.plantarum for 6h stained significantly high for ZO-1 in 
comparison with those that were not treated with L.plantarum. They did not find the same 
result for OC. They also found that pre-treatment of Caco-2 cells with L.plantarum for 6h led 




to significant protection against barrier dysfunction caused by phorbol 12,13-dibutyrate 
(PDBu) (Karczewski et al., 2010). These results indicate that L.plantarum improves the 
intestinal barrier function and may prevent the entry of antigens or pathogens present in the 
colonic lumen. 
Kelly-Quagliana et al. determined and compared the effect of diets containing10g/100g 
cellulose (C), oligofructose (OF) or inulin (I) food on the immune function of 32-35 days old 
B6C3F1 female mice. They found that mice that were fed OF and I diets had higher natural 
killer cell activity from splenocytes and greater phagocytic activity of peritoneal 
macrophages in comparison with mice fed C diet. Mice fed OF and I diets also up-regulated 
macrophage-dependent (T-helper 1 type) immune responses (Kelly-Quagliana et al., 2003). 
In conclusion, these studies are examples of how IBD could be prevented or treated through 
various mechanisms – changing the microflora, improving the intestinal barrier function or 
improving the immune response. One of the best ways to influence these changes is by 
increasing the intake of dietary fiber. 
Diet has a major influence on the gut microbiome and intestinal epithelium. The gut 
microbiome can be altered by consumption of fiber-rich diet. The fiber-rich diet provides the 
necessary source of energy for the microbiome to thrive and the short chain fatty acids 
(SCFA) that are produced through microbial fermentation are used by the intestinal 
epithelium in the form of energy. Butyrate is one of the SCFA produced by microbial 
fermentation. Butyrate plays an important role in the growth, proliferation and differentiation 
of gut epithelial cells (Guilloteau et al., 2010) It helps in protection against colorectal cancer 
by either causing the neoplastic cells to differentiate or by inducing apoptosis in them 
(Brouns et al., 2002; Guilloteau et al., 2010). Butyrate has anti-inflammatory properties and 




has been shown to suppress the pro-inflammatory marker, IL-8 and it also improves the 
intestinal barrier function (Gibson & Rosella, 1995; Gibson et al., 1999; Guilloteau et al., 
2010). Hence, improving the dietary fiber consumption of IBD patients might be an effective 
strategy combating the disease.  
DIETARY FIBER 
What is dietary fiber (DF)?  
The definition of DF has evolved over time. Numerous countries and organizations define 
DF in different ways. But the definition developed by  CODEX Alimentarius Commission 
(CAC) is accepted by 180 countries, making it an international standard for food and 
international trade  (Jones, 2014). The definition states that:  
Dietary fibre means carbohydrate polymers
1
 with 10 or more monomeric units
2
, which are 
not hydrolysed by the endogenous enzymes in the small intestine of humans and belong to the 
following categories: 
1. Edible carbohydrate polymers naturally occurring in the food as consumed. 
2. Carbohydrate polymers, which have been obtained from food raw material by physical, 
enzymatic or chemical means and which have been shown to have a physiological effect of 
benefit to health as demonstrated by generally accepted scientific evidence to competent 
authorities.  
3. Synthetic carbohydrate polymers, which have been shown to have a physiological effect of 
benefit to health as demonstrated by generally accepted scientific evidence to competent 
authorities. 




Footnote 1 states, “when derived from a plant origin, dietary fibre may include fractions of 
lignin and/or other compounds associated with polysaccharides in the plant cell walls. These 
compounds also may be measured by certain analytical method(s) for dietary fibre. 
Footnote 2 states that, “Decision on whether to include carbohydrates of 3 to 9 monomeric 
units should be left up to national authorities.” 
Most governments accept this definition, with slight modifications in the inclusion criteria 
for carbohydrates with more than two monomeric units, non-starch polysaccharides, resistant 
starch, resistant oligosaccharides and resistant maltodextrins.  
Non-starch polysaccharides are defined as “the skeletal remains of plant cells that are 
resistant to digestion by enzymes of man measured as non α-glucan polymers measured by 
the Englyst (Type 2 Method).  It includes NSP, which is comprised of cellulose, 
hemicelluloses, pectin, arabinoxylans, beta-glucan, glucomannans, plant gums and mucilages 
and hydrocolloids, all of which are principally found in the plant cell wall. It does not include 
oligosaccharides, resistant starch and resistant maltodextrins” (Jones, 2014). 
Codex Alimentarius Commission issued a new definition in 2009, for dietary fiber to include 
resistant starch under carbohydrate polymers obtained from food raw material by physical, 
enzymatic or chemical means. 
How is dietary fiber characterized?  
Dietary fiber can be categorized based on various characteristics like: (a) chemical structure 
(sugar identity, linkage type, size) (b) food properties (biological origin, food processing) (c) 
gastrointestinal fate (rate of digestion and absorption) (d) metabolic properties (Glycemic 
index, substrate metabolism, fermentability and fermentation products, prebiotic effect) and 
(e) health effects (Englyst et al., 2007).  




There are different types of dietary fibers with varying chemical structures that would alter 
its properties like water-solubility, viscosity, digestibility and fermentability. For example, 
cellulose found in foods like whole grains, fruits and vegetables is a polysaccharide 
consisting of β-(1→4)-linked glucose molecules. Cellulose polymers linked this way forms a 
rigid, insoluble and poorly fermentable structure. In the gastrointestinal tract cellulose has 
little impact, because as per an in vitro study by Barry et al., only 6-7% of cellulose was 
found to be fermentable. On the other hand, β-glucan found in cereals like oats and barley are 
made up of β-(1→4)-linked glucose molecules, with intermittent β-(1→3)-linkages every 2-4 
glucose units. The β-glucan produced by yeast and mushrooms consists of β-(1→3)-linkages 
as the backbone and β-(1→6)-branches. This chemical structure makes β-glucan a soluble 
and highly fermentable dietary fiber. In the gastrointestinal tract, β-glucan increases the 
viscosity of the digesta which in turn reduces the rate of gastric emptying from the stomach 
to the small intestine; lowers absorption of nutrients and motility of small intestine; increases 
satiety; and increases fermentability in the large intestine(Mälkki & Virtanen, 2001). 
Other types of dietary fibers that are insoluble include resistant starch, chitin, inulin and 
arabinoxylan and those that are soluble include chitosan, arabinogalactan, pectins, guar gum, 
xanthan gum, gellan, alginate, carrageenan, polydextrose, fructo-oligosaccharides, galacto-
oligosaccharides and lactulose. These dietary fibers also vary in viscosity, fermentability and 
digestibility. Thus they have different effects in the gastrointestinal tract. For example, 
pectins and gums are soluble, viscous and highly fermentable fibers. The viscous nature of 
pectins and guar gum may enhance the mucous layer that protects the gastric lining from 
ulceration. The soluble nature of these dietary fibers also delays gastric emptying because of 
their water-holding capacity – leading to increased satiety, slower absorption of glucose and 




fecal bulking. On the other hand, prebiotics like inulin and fructooligosaccharide are 
indigestible in the small intestine but highly fermentable in the colon. These dietary fibers 
selectively stimulate the growth of beneficial bacteria in the colon and thus improve the 
colon health (Rose & Hamaker, 2011).   
To summarize, dietary fibers can be characterized by its physico-chemical properties, 
gastrointestinal fate, or the physiological or health effect they impart.  
How is dietary fiber digested in the gut? 
In the process of digestion, carbohydrates are first broken down by the salivary α-amylase in 
the mouth. Digestion of the carbohydrates in the stomach is limited. Carbohydrates are 
mainly digested in the small intestine. The pancreas secretes α-amylase which is delivered to 
the small intestine. The pancreatic α-amylase breaks down carbohydrates to 
monosaccharides, disaccharides like maltose and sucrose and oligosaccharides. The brush 
border enzymes of the small intestine break down the disaccharides and oligosaccharides into 
monosaccharides like glucose, galactose and fructose. However, not all carbohydrates 
present in the food is digestible in the small intestine. So the indigestible carbohydrates reach 
the large intestine, which is then fermented by the gut microbiota present there. The gut 
microbes break down the indigestible carbohydrates to short chain fatty acids (SCFA) like 
acetate, propionate, butyrate, iso-butyrate and more. 85% - 95% of the SCFA thus produced 
consists of acetate, propionate and butyrate. These short chain fatty acids have been known to 
have positive effect on the health of the host(Cummings & Macfarlane, 1991; Guilloteau et 
al., 2010).  
 
 




What is the physiological significance of dietary fiber? 
Dietary fiber has been shown to exert beneficial effects on body weight, food intake, glucose 
homeostasis, and insulin sensitivity (Den Besten et al., 2013). In a review by Galisteo et al., 
several human and animal studies were summarized to indicate a correlation between higher 
fiber intake and a reduced risk of metabolic syndromes - obesity,  cardiovascular disease and 
diabetes (Galisteo et al., 2008). An inverse relation between fiber intake and the risk of 
developing IBD has also been established (Ananthakrishnan et al., 2013). Ananthakrishnan et 
al. collected and analyzed data from 170,766 women who had participated in the Nurse’s 
Health Study. Dietary information was collected by administration of semi-quantitative food 
frequency questionnaire every 4 years, for up to 26 years. Additionally, medical records were 
checked to confirm self-reported CD or UC. Using the Cox proportional hazards models, 
they concluded that the cohort of women who consumed the highest amounts of dietary fiber 
had 40% lower risk of developing CD in comparison with women who consumed lowest 
amount of dietary fiber. No such association was observed for UC (Ananthakrishnan et al., 
2013). For the purpose of this study, we will focus on the physiological effect of dietary fiber 
only on IBD.  
Several cell culture, animal and human studies have been conducted to determine the role of 
dietary fiber in IBD: 
Human Studies: Hallert et al. found that UC patients in remission who were fed 60g oat 
bran every day for 12 weeks as compared to UC patients in remission who did not receive the 
oat bran treatment, adapted to the diet leading to reduction of butyrate concentration. They 
observed 1.3 fold increase at 4wk and 8wk, but the concentration of butyrate normalized by 
12 weeks and returned to its original concentration (Hallert et al., 2003). 




In an 8-week, randomized, single blind, cross-over study, James et al. compared the effect of 
increased dietary fiber in ulcerative colitis (UC) patients in remission with healthy subjects 
on food intake, bowel symptoms and tolerability, fecal indices and whole gut transit time 
(WGTT). During the dietary intervention period designated as ‘low RS/WB’, the participants 
consumed breads, cereals and muffins containing 2-5 g resistant starch (RS) and 2-5 g wheat 
bran (WB) per day, for 17 days. During the period of dietary intervention designated as 'high 
RS/WB', participants consumed breads, cereals and muffins containing 15g RS and 12g WB 
per day, for 17 days. There was a wash-out period of 14 days between each dietary 
intervention period, in this cross-over study.  
At baseline, there were no significant differences between the UC patients and healthy ones 
in terms of fecal weight, pH, SCFA and phenolic compounds or WGTT. But at baseline, UC 
patients consumed significantly less iron and zinc. UC patients also consumed 1.5 times 
lesser amount of dietary fiber, which was not statistically significant. In spite of lower 
consumption of dietary fiber, output of fecal starch and NSP was three-fold higher in UC 
patients (James et al., 2015).  
Post-intervention, the researchers observed that during the ‘high RS/WB’ intake period, both 
subject groups consumed significantly higher amount of fiber as compared to the baseline, as 
expected. Both groups tolerated the ‘low RS/WB’ and ‘high RS/WB’ diets well. During the 
‘high RS/WB’ intervention period, healthy controls excreted more than double amount of 
fecal starch and NSP as compared with baseline, but no differences were found in UC 
patients. Post-intervention, there were no significant differences between the UC patients and 
healthy ones in terms of fecal weight, pH, SCFA and phenolic compounds or WGTT. But 
usage of NSP was significantly reduced in UC patients as compared with healthy ones, 




during either dietary intervention periods. Abundance of microbiota was similar in UC 
patients and healthy ones, but the composition was different, with UC patients having more 
diverse microbiota in their Clostridium cluster XIVa (James et al., 2015).  
Both groups tolerated both diets well. The only changes that were observed in this study were 
– two-fold increase in excretion of fecal starch and NSP in healthy patients, as compared 
with baseline; reduction in the usage of NSP in UC patients compared with the healthy ones; 
and differences in the diversity of gut microbiota. The researchers attributed these differences 
to lower fermentative capacity of NSP in UC patients as compared with healthy ones (James 
et al., 2015).  
In conclusion, increasing the dietary fiber intake of UC patients increased the butyrate 
concentration in the colon, which was normalized during long-term usage. High consumption 
of resistant starch also alters the microbial numbers and diversity in both – healthy and UC 
patients in remission. However, James et al. did not observe any significant changes in the 
fecal indices of UC patients when they were on high RS/WB diet. This could be because of 
dosage and type of fiber was not effective. The type and dosage of fiber may also have an 
effect on IBD markers.  
Animal Studies: Zhou et al. found that when 21 days old, weaned Huanjiang piglets were 
fed standard diet supplemented with 0.5% soybean oligosaccharide (n=5, experimental 
group) as opposed to 0.5% corn starch (n=5, control group), the concentration of butyrate 
increased by 1.5 fold and the mRNA expression of IL-8 decreased by 26%, in the colonic 
contents obtained from the piglets after 14 days (Zhou et al., 2014b). 
Le Blay et al., found that when Wistar rats were fed a standard diet supplemented with 
9g/100g diet of fructooligosaccharide (FOS), there was 1.3 fold increase in the cecal SCFA 




concentration after 2 wk, 8wk and 27wk; and, 3 fold increase in the butyrate concentration 
after 2 wk, and 27 wk, but 5 fold increase after 8 wk. Reduction in the butyrate concentration 
at 27 wk suggests that the rats adapted to the FOS supplemented diet and may have an 
increased number of FOS degrading gut bacteria (Le Blay et al., 1999). Similar results of 
adaptation leading to decreased butyrate concentration were observed in the human study by 
Hallert et al., 2003. 
Nishitani et al. determined the anti-inflammatory effect of Lentinan - Letinula edodes 
derived β-1,3; 1,6-glucan on 7-week old C57BL/6CrSlc mice that were induced to develop 
colitis when treated with 2% DSS w/v in drinking water for 7 days. Through intragastric 
administration, different doses of lentinan - 50, 100 or 200 µg/mouse, were administered 
daily for 7 days prior to colitis induction via DSS and continued until sacrifice - 3 days after 
stopping the DSS-treatment. DSS- treated mice that received 100µg lentinan through oral 
administration, had significantly reduced weight loss (by 1.1-fold), colon shortening (by 1.2-
fold) and histological score (by 60%), as compared with DSS-treated mice that did not 
receive lentinan. Additionally, lentinan treated DSS-mice significantly reduced the mRNA 
expression of pro-inflammatory cytokines IL-1β by 50% in 200µg/mouse lentinan group and 
INF-γ by 40% in 100 and 200µg/mouse lentinan group as compared with untreated mice. 
This study suggests that the dietary fiber, β-glucan has anti-inflammatory properties that may 
help in ameliorating IBD (Nishitani et al., 2013). 
Majumder et al. determined the effect of isomaltodextrin (IMD) on the inflammatory 
markers found in DSS-induced colitis mouse model. Mice were provided with one of the 
doses - 0.5,1.0,2.5,5.0 % w/v IMD in drinking water for 23 days. On day 15, 5% DSS was 
added to the water until end of the experiment (day 23) to induce acute colitis. In contrast 




with Nishitani et al., IMD was not effective in improving the weight loss or colon shortening 
that occurs due to colitis. But, all doses of IMD was effective in reducing the concentration 
of pro-inflammatory cytokines TNF-α and IL-6 in DSS-treated mice as compared with those 
who did not receive IMD treatment. They also observed a tendency but not significant 
difference in reduction of other pro-inflammatory markers IL-1β, MCP-1, and IL-17 and an 
increase in anti-inflammatory marker IL-10 – suggesting that IMD may be protective against 
colitis-induced gut inflammation (Majumder et al., 2017).   
Le Leu  et al., determined the effect of consumption of red meat with and without resistant 
starch on severity of DSS-induced colitis induced in male Balb/c mice. Colitis was induced 
in mice through 3% DSS in drinking water for the first 5 days of the dietary treatment. For 
the remaining 7 days of the treatment, they received plain drinking water. The daily disease 
activity index (DAI) increased in all dietary groups: control, red meat (RM), resistant starch 
(RS) and RM+RS. DAI was higher in the red meat group as compared with control and RS 




 day of the experiment, there 
were no significant differences in any dietary groups. Histology scores were also 
significantly higher in the red meat group as compared with control and RS groups. Resistant 
starch appeared to be protective against the deteriorating effect of red meat, as indicated by 
the lower DAI scores than the RM group, but there was no statistical significance (Le Leu et 
al., 2013). Although the researchers concluded that red meat aggravates DSS-induced colitis 
in mice, it should be noted that this was a short term study and the differences in DAI scores 
were not significant on last two days of the experiment. Hence, this study cannot be 
extrapolated to long term effects of red meat. 




Scarminio et al. determined the protective effect of feeding green dwarf banana flour that is 
rich in type 2 resistant starch to male Wistar rats for 21 days. Colitis was induced by 
administration of trinitrobenzenesulfonic acid (TNBS)- for last 7 days of the experiment. 
Biochemically, the colonic damage caused by colitis was characterized by a reduction in 
colonic glutathione (GSH) levels and an increase in alkaline phosphatase (AP) and 
myeloperoxidase (MPO) activity. GSH is a marker of anti-oxidation and MPO and AP are 
markers of inflammation. The researchers found that feeding 20% banana flour diet 
significantly lowered the macroscopic and microscopic colonic damage score, maintained 
GSH levels and decreased AP and MPO levels in diseased mice as compared with non-
diseased ones. They concluded that green dwarf banana flour helps in prevention and 
treatment of IBD mediated by its anti-oxidant and anti-inflammatory properties (Scarminio et 
al., 2012).  
Bassaganya-Riera et al. compared the protective effect of various soluble fibers and resistant 
starch against gut inflammation in wild type (WT) and IL-10 (IL-10
-/-
) deficient C57BL/6J 
mice. IL-10
-/-
 mice tend to develop IBD, due to the lack of anti-inflammatory cytokine, IL-
10. The researchers tested how diet supplemented with 4g fiber/100g diet affected the 
development of IBD in WT and IL-10
-/-
 mice. The fibers tested were PROMITOR soluble 
corn fiber (SCF), STA-LITE III polydextrose (PDX), Biogum (BG), Pullulan (PI-20), 
PROMITOR resistant starch-75 (RS-75), SCF&BG, RS-75&BG and inulin. They used 
dietary disease index (DAI), histology scores and cytokine production as biomarkers of gut 
inflammation. In IL10
-/-
 mice RS-75, SCF, RS-75&BG, and inulin suppressed IBD 
development by decreasing DAI. RS-75 and inulin were the only fibers that decreased 
inflammatory lesions in ileum and the colon of IL10
-/- 
mice. RS-75, SCF, and inulin 




suppressed the production of pro-inflammatory cytokine interferon-γ (INFγ) and RS-75 
increased the production of IL-10-expressing cells in WT mice. These results suggest that 
RS-75, SCF and inulin are protective against gut inflammation (Bassaganya-Riera et al., 
2011). 
Moreau et al. compared the effect of time and type of dietary fiber supplementation on the 
efficiency of improving intestinal mucosa through SCFA production, in DSS-induced colitis 
model of male Sprague-Dawley rats. The diets compared were basal diet (BD), basal diet 
supplemented with type-3 resistant starch (BD+RS) and basal diet supplemented with 
fructooligosaccharide (BD+FOS). Colitis was induced by adding 50g DSS/L to the water of 
the DSS group for 7 days and all of them were fed the basal diet during this time. The control 
group received only water. Then, the DSS concentration was reduced to 30g DSS/L for rest 
of the experiment, and during that time, the mice received the experimental or basal diets. 
The effect of different diets was observed at 7 days and 14 days after starting the dietary 
intervention. Therefore, at each time point 6 groups were compared: BD-control, FOS-
control, RS-control, BD-DSS, FOS-DSS and RS-DSS. In the control group, there were no 
significant changes due to diet on any parameters - food intake, body weight, disease activity 
index (DAI) or histological score. Between day 7 and day 14, there was a 1.2-fold reduction 
in food intake only in the FOS-DSS group, when compared with RS-DSS group (p = 0.047). 
At day 7, the body weight gain was 4-times and 6-times lower in the FOS-DSS compared 
with BD-DSS and RS-DSS groups, respectively (p<0.05). At day 14, the body weight gain 
was 4-times and 9-times lower in the FOS-DSS when compared with BD-DSS and RS-DSS 
groups, respectively (p<0.05). There was a 2-fold decrease in the DAI score in the RS-DSS 
group as compared with BD-DSS and FOS-DSS groups. At day 14, the histological score of 




the RS-DSS group was 3 times lower than BD-DSS (p=0.0082) and FOS-DSS (p=0.0306) 
groups. The total histological score was significantly lower for RS-DSS when compared with 
BD-DSS (p=0·0008 at day 7, p=0·0124 at day 14) and FOS-DSS (p=0·0195 at day 7, 
p=0·0406 at day 14). DSS treatment decreased the SCFA concentration in the cecal-colonic 
contents of RS-DSS and FOS-DSS groups when compared with healthy controls; and, the 
butyrate concentration was higher in the cecum of rats in the RS-DSS group as compared 
with BD-DSS and FOS-DSS groups. In conclusion, RS diet seemed to improve the condition 
of inflamed colons, but FOS did not (Moreau et al., 2003). 
In a double-blind, placebo-controlled, randomized trial in canines, Segarra et al. determined 
the effect of a dietary supplement that contained chondroitin sulfate (CS) and prebiotics 
(resistant starch, β-glucans and mannanoligosaccharides (MOS)) on clinical disease activity, 
intestinal histology, gut microbiota, and selected serum biomarkers in dogs suffering from 
IBD, over 180 days. There were no significant differences in clinical disease activity and 
fecal gut microbiota between the placebo group and the supplemented group at any time 
point. However, there was a significant decrease (1.53-fold; p< 0.01) in the median overall 
histology score of the supplemented group, after treatment. Although the median overall 
histology score decreased by 1.07-fold in the placebo group after treatment, the difference 
was not significant. Higher concentration of serum cholesterol has been associated with 
better histologic score and they found significantly higher serum cholesterol (p <0.05) after 
60 days of treatment in the supplement group. Increased serum concentration of 
paraoxonase-1 (PON1), an antioxidant enzyme is associated with decreased oxidative stress 
and inflammation. The researchers found that after 60 days of dietary supplementation, there 
was a significant increase in the serum concentration of PON1 as compared with the placebo 




group. The placebo group also showed significantly reduced serum total antioxidant capacity 
(TAC) levels after 120 days (p< 0.05), which could also be associated with increased 
oxidative stress. These results suggest that dietary supplements made of natural 
glycosaminoglycan – chondroitin sulfate and prebiotics helped in reduction of oxidative 
stress caused by IBD (Segarra et al., 2016). 
To summarize, SCFA production is increased with increased intake of DF. DF intake leads to 
an increased concentration of butyrate in the colon, probably because of the presence of high 
numbers of butyrate-producing microbes (Le Blay et al., 1999; Zhou et al., 2014a).  DF has 
anti-inflammatory effect in vivo (Nishitani et al., 2013; Majumder et al., 2017) against colitis 
induced gut inflammation. DF may also impart its protective effect against IBD through its 
anti-oxidant properties (Scarminio et al., 2012); and, resistant starch may be protective 
against the aggravation of IBD due to red meat consumption (Le Leu et al., 2013). 
Cell culture: The study done by Chen et al. is very similar to our experimental design. Chen 
et al. subjected four dietary fibers – raw potato starch (RS2), fructooligosaccharides (FOSs), 
sorghum arabinoxylan (SAX) and corn arabinoxylan (CAX) to in vitro digestion by 
sequentially exposing them to human salivary α-amylase, pepsin and pancreatin. The digesta 
(except for FOS) was then dialyzed against purified water for 24h and then freeze-dried. 
Fecal samples were obtained from three healthy individuals and mixed equally in phosphate-
buffered saline to prepare a fecal inoculum. 50mg of each fiber was fermented with 5% fecal 
inoculum for 12h. The fermenta products were collected and centrifuged. The supernatants 
were filter-sterilized and subjected to the cell monolayers. SAX fermentation produced 
highest amount of total SCFA followed by FOS then CAX and then RS2. In terms of 
butyrate concentration, FOSs produced highest amount of butyrate, followed by SAX, then 




CAX and then RS2. Chen et al. claim that RS2 did not ferment well in this experiment. 
Among the dietary fibers, they found that the intestinal integrity of the cells was improved by 
FOS, SAX, CAX when compared with RS2. 
They then grew Caco-2 cells to confluence on Transwell plates for 7 days and subjected them 
to either pure SCFA mixture or sterilized fiber-fermented supernatants for 48h and measured 
the trans-epithelium resistance using a volt-ohm meter and paracellular permeability using 
fluorescent spectrophotometry. Caco-2 cells were exposed to one of the SCFA mixes 
(combination of acetate, propionate and butyrate) containing 10, 20 or 50% butyrate while 
maintaining the total SCFA concentration at 40mM for all mixes. They found that SCFA 
mixes containing 20% (8mM) and 50% (20 mM) butyrate had increased the TEER values by 
1.3-fold and 1.5-fold, respectively, as compared to control (no SCFA added). Only butyrate 
showed a positive correlation with TEER values, suggesting that butyrate improves the 
intestinal barrier function (Chen et al., 2017). 
To determine the reparative effects of SCFA, Caco-2 cells were inflamed by addition of 
10µg/ml LPS on apical side and 50ng/ml TNFα on the basolateral side for 48h. Inflamed 
Caco-2 cells were then exposed to one of the SCFA mixes (combination of acetate, 
propionate and butyrate) containing 5, 20 or 50% butyrate while maintaining the total SCFA 
concentration at 40mM for all mixes. To determine the protective effects, Caco-2 cells were 
exposed to the inflammatory stimulus and SCFA mixes simultaneously. Increasing 
proportion of butyrate improved barrier function in both –inflamed and non-inflamed Caco-2 
cells (Chen et al., 2017).  
In order to determine the molecular mechanism through which IMD imparts its anti-
inflammatory effect, Majumder et al. subjected ~80% confluent intestinal epithelial cells, 




HT-29 to 0.01, 0.05, 0.1, 0.5 or 1 mg/ml IMD for 2h, followed by 10 ng/ml TNF-α induced 
inflammation for 4h and measured the secretion of pro-inflammatory marker IL-8 in the 
supernatant. To determine the role of Toll-like receptor (TLR)-4 in the anti-inflammatory 
effect of IMD, HT-29 cells were pre-treated with TLR-4 inhibitor – CL-095 for 6h before 
being exposed to different concentrations of IMD for 2h and then TNFα for 4h, as mentioned 
before. They found that 0.05 mg/ml – 1mg/ml IMD inhibited the expression of IL-8 in 
inflamed cells, as compared to inflamed cells that were not treated with IMD. They also 
determined that the presence of TLR-4 inhibitor along with IMD, further reduced the 
expression of IL-8 in inflamed HT-29 cells. After this observation, they tested for expression 
of TLR-4 receptors in the mouse colonic tissue and found that there was a significant 
reduction in it in the DSS-induced colitis mice that were treated with 5% w/v IMD. These 
results indicate that IMD imparts its anti-inflammatory effect by suppressing TLR-4 
receptors (Majumder et al., 2017). 
To summarize, dietary fibers have been shown to be protective against inflammation, in 
vitro. This protective effect of dietary fiber was attributed to the increased production of 
butyrate due to microbial fermentation. To prove this Chen et al. tested the effect of pure 
SCFA on the intestinal integrity of Caco-2 cells and found that SCFA mixes containing 20% 
and 50% butyrate improves the intestinal integrity of inflamed Caco-2 cells. 
General conclusions regarding dietary fiber and IBD 
SCFA production is increased with increased intake of DF. DF intake leads to an increased 
concentration of butyrate in the colon, probably because of the presence of high numbers of 
butyrate-producing microbes (Le Blay et al., 1999; Zhou et al., 2014a).  DF has anti-
inflammatory effect in vivo (Nishitani et al., 2013; Majumder et al., 2017) against colitis 




induced gut inflammation. DF may also impart its protective effect against IBD through its 
anti-oxidant properties (Scarminio et al., 2012). Resistant starch may also be protective 
against the aggravation of IBD due to red meat consumption (Le Leu et al., 2013). These 
beneficial effects of dietary fibers have been attributed to increased concentration of SCFA, 
specifically butyrate (Chen et al., 2017). The studies that looked at the effect of SCFA on 
symptoms or markers of IBD are reviewed below. 
SHORT CHAIN FATTY ACIDS (SCFA) 
What are SCFA? 
The gut microbiota in the large intestine ferment indigestible dietary fiber and resistant 
starches into SCFA. SCFA are one to six carbon organic acids; and the most abundant SCFA 
in the large intestine are acetate (C2), propionate (C3) and butyrate (C4). They are found in 
an approximate molar ratio of 60:10:10 in the gut (Cummings, 1981). 
What is the role of butyrate in IBD? 
Several studies have been conducted to determine the role of butyrate in IBD: 
Human studies: The butyrate enema studies conducted in humans are summarized in 
Table1. Most of the studies listed here indicate either an improvement or no effect of butyrate 
enema on disease activity, histology score, endoscopic score and alleviation of symptoms 










Table 1: Butyrate enema studies conducted in humans. 







double blind study 
Placebo: saline  enema, n = 6 
Trt: Mix of 60 mM Ac, 30 mM Pr and 
40 mM Bu enema, n=7 
Dose and frequency: Twice a day for 
14 days 
↔ Endoscopic score at 
the end of treatment 
period 
↔ Histology score at 









double blind study 
Placebo: saline enema, n = 19 
Trt: 60 ml of 80 mM butyrate enema, 
n = 19 
Dose and frequency: Once a day for 6 
weeks 
↔ Disease Activity 
Index (UCDAI) score 
at the end of treatment 
period 
↔ Endoscopic score at 
the end of treatment 
period 
↔ Histological score 





















Placebo: 60 ml saline enema, n=12 
Trt = 60 ml of 40 mM butyrate enema, 
n =12 
Dose and frequency: Twice per day 
for 2 weeks; Washout period: 1 week 
↔ Endoscopic score at 
the end of treatment 
period 
↔ Histological score 
at the end of treatment 
period 
↔ Symptom score at 






































Randomized, placebo-controlled, double 
blind study 
Placebo (C): saline, n = 5 
Trt (T): 60 mL mix of 60 mM Ac +30 
mM Pr + 40 mM Bu enema, n= 9 
Dose and frequency: Twice daily for 5 
weeks (therapeutic phase - TP) 
Follow up for up to 6 months after 
treatment 
TP: Compared with 
baseline, ↓ number of 
days/week for rectal 
bleeding (p<0.01) in 
treatment group 
compared to placebo 
group 
Follow up: Compared 
with baseline, ↓ number 
of days/week for  rectal 
bleeding but not 
significant (p =0.13) 
TP: ↓ Endoscopic score  
(p < 0.001) for SCFA 
group, ↓ Endoscopic 
score (p<0.01) for 
placebo 
Follow up: ↔ 
Endoscopic score , ↔ 
Histological score at 
the end of the treatment 
period 
 










Placebo: Saline enema, n = 5 
Trt: 60ml of 100 mM butyrate enema, 
n =6 
Dose and frequency: Twice daily for 8 
weeks 
↓ Disease activity 
index (DAI) after 4 
wks (p=0.011 ) and 8 
wks (p=0.001) of 
treatment in the 
butyrate-treated 
patients 
↓ Endoscopic score 
only after 8 wks of 
treatment (p=0.007) in 
the butyrate-treated 
patients. 
↔ Overall histological 
score between groups 


























Crossover study, placebo controlled 
10 trts: 3 saline infusions (at the start, 
middle and end of the study) and 
7 SCFA infusion in random order: Ac, 
Pr, Bu, Ac+Pr, Ac+Bu, Pr+Bu, 
Ac+Pr+Bu 
Concentration used for trts Ac: 60 
mM, Pr: 20 mM, Bu: 20 mM 
Volume: 300 ml of test solution; 
Washout period: 3 days 
% absorption of 
butyrate > % 
absorption of acetate 
% absorption of 
butyrate not greater 
than  % absorption of 
propionate 
Total SCFA absorbed 
was positively 
correlated to the total 
SCFA concentration 
infused, except for 
APB 
Amount of Ac 
absorbed from APB 
solution was 
negatively correlated 













(Table 1 continued) 
(Hamer et 
al., 2009) 
Healthy Double blind, placebo-controlled, 
crossover study 
Placebo: 60 mL saline, n =16 
Trt:  60 mL of 100 mM butyrate 
enema, n = 16 
Dose and frequency: Once a day for 
two weeks 
↔ Histological score 
at the end of the 
treatment period 
↓ Oxidative stress at 










Placebo: 60 mL saline, n = 18 
Trt: 60 mL 100 mM butyrate enema, n 
= 17 
Dose and frequency: Once a day for 
20 days 





↔ Histology score 
between the treatment 
and placebo groups 





















double blind study 
Placebo: 30 ml saline enema, n = 7 
Trt: 30 ml of 600 mM butyrate enema, 
n = 10 
Dose and frequency: Twice daily for 
30 days 
↓Endoscopic score in 
butyrate-treated 
patients, as compared 
with baseline (p = 
0.0083) 
↔ Histological score 
in either groups 
↓ Atrophy score in trt 
group as compared 
with baseline, but not 
significant 
 
Animal studies: Argenio et al. tested the effect of 80 mM butyrate enema in trinitrobenzene-
sulphonic acid (TNBS) colitis induced model, in Wistar rats. 2 weeks of butyrate treatment 
led to a 2.5-fold reduction in the macroscopic score and nearly 3-fold reduction in the 
histological scores when compared with rats that received only saline enema. They also 
tested for the effect of 80 mM butyrate on development of colitis associated colorectal 
cancer. One week after induction of colitis with TNBS in Wistar rats, the researchers 
administered azoxymethane (AOM) for 5 weeks and continued treatment until 27 weeks. 
They found that butyrate treatment led to a 2-fold reduction in the number of tumors formed 
and >3-fold reduction in the size of the tumors when compared with saline treatment (D' 
Argenio et al., 2007).  




Vieira et al. determined the effect of oral administration of 0.5% butyrate for 14 days on the 
histological score and cytokine profile and DSS-induced colitis C57BL/6 mice. The crypt 
length was reduced by 50% in the UC-mice that were fed the standard diet, when compared 
with control mice that were on standard diet. But the UC-mice that were fed the diet 
containing butyrate, the crypt length was 1.5-fold longer than UC-mice on standard diet. 
They also found that UC-mice that were fed butyrate-supplemented diet had half the 
concentration of neutrophils and eosinophils when compared with UC-mice on standard diet. 
They also observed an improved inflammatory cytokine profile in the butyrate-fed UC-mice 
(Vieira et al., 2012). 
General conclusions from human and animal butyrate enema studies 
The human studies suggest that for the treatment to be effective the butyrate concentration 
should be ≥100 mM and the treatment should be given for at least 6-8 weeks to observe an 
improvement in the severity and symptoms of colitis. The concentration and number of days 
for treatment is reduced in the rodent studies, probably because of lower body weight and 
size. But it is important to note that dietary fiber fermentation also produces other SCFA like 
acetate, propionate. Additionally, other branched chain-fatty acids like iso-butyrate, valerate 
etc., which are fermentation products of amino acids; organic acids like lactate and succinate 
and products like indoles, phenols, amines and ammonia are also present in the colonic 
lumen(Cummings & Macfarlane, 1991). Although, 85% - 95% of the products contain 
acetate, propionate and butyrate – indicating that they are present in highest amounts in the 
colon (Cummings & Macfarlane, 1991). 
Most of the enema studies reviewed above have looked at the effect of only butyrate on the 
mucosal damage caused by IBD. Only 3 groups of researchers reviewed above tested for the 




effect of enemas containing acetate, propionate and butyrate (Guillemot et al., 1991; Pinto et 
al., 1999; Vogt & Wolever, 2003). Hence, to determine the protective effect of dietary fibers 
more realistically, it is important to study the effect of its fermentation byproducts in the 
presence of other colonic lumen particles. However, only the concentrations of acetate, 
propionate and butyrate are well characterized in the colon. Hence, the focus of our research 
is to determine the effect of increased butyrate in the presence of acetate and propionate on 
the intestinal integrity and secretion of pro-inflammatory chemokine, IL-8 in Caco-2 cells. 
INTERLEUKIN-8 (IL-8) 
What is IL-8? 
IL-8 is an pro-inflammatory marker belonging to IL-1family (Guan & Zhang, 2017). IL-8 
belongs to the class of chemokines that have the cysteine – amino acid – cysteine (CXC) 
structure and binds to CXC receptors (CXCR) on the cells. IL-8 binds to CXCR1 and 
CXCR2 (Kobayashi, 2006). The primary role of IL-8 is the activation and migration of 
neutrophils from the peripheral blood into the tissues (Műzes et al., 2012). When acute 
inflammation occurs, IL-8 is secreted from the epithelial cells that bind to the CXCR2 on 
neutrophils. IL-8 thus acts as a chemo-attractant for neutrophils, which then migrate and 
infiltrate the injured tissue (Kucharzik & Williams, 2003; Kobayashi, 2006).  
What is the role of IL-8 in IBD? 
One of the inflammatory markers used to characterize IBD is IL-8. Gibson and Rosella 
isolated colonic crypt cells from the resected mucosa of patients with varied colon diseases: 
normal (n=16), colorectal cancer (CRC) (n = 20), Ulcerative colitis (UC) (n=17) and Crohn’s 
Diseases (CD) (n=14). The isolated cells were then cultured for 16-24 hours and IL-8 
secretion was measured in the supernatant by ELISA. They found that IL-8 secretion was 2.5 




times higher from the uninflamed mucosa of colonic crypt cells that were isolated from UC 
and CD patients, as compared with that of normal patients (Gibson & Rosella, 1995). 
In a recent study by Rodriguez-Peralvarez et al. the serum cytokine profile of UC patients 
(n=67), was characterized and compared with that of healthy ones (n=21), with the goal of 
determining the serum biomarkers that could be used to diagnose UC. Using the univariate 
analysis they determined that IL-6 was 1.8-times higher (p=0.007), IL-8 was 1.3 times higher 
(p=0.002) and IL-10 was 1.3 times higher (p=0.008) in UC patients when compared with 
healthy ones. Using the multiple logistic regression model they showed that UC patients were 
characterized by higher concentration of IL-8 (odds ratio [OR] = 1.37, p=0.002) and IL-10 
(OR = 3.88, p=0.012) and lower concentration of IFN-γ (OR = 0.95, p=0.002). This serum 
profile had 74.6% sensitivity, 85.7% specificity, and 77.3% accuracy in discriminating 
between UC patients and controls. When the data from only newly diagnosed patients were 
used, the accuracy of the model increased to 96.4% accuracy. Higher serum concentration of 
IL-8 was also related to moderate to severe disease clinical activity (OR=1.16, p=0.012); 
endoscopic (OR=1.10, p=0.026) and histology (OR = 1.33, p=0.017) severity (Rodríguez-
Perálvarez et al., 2012) 
In conclusion, IL-8 concentration is high in the serum and colonic crypt cells of UC patients 
and could possibly be used as a biomarker for diagnosis. 
How is IL-8 affected by butyrate? 
Several studies indicate that butyrate suppresses the secretion of IL-8 from colonic cells: 
Gibson and Rosella isolated uninflamed colonic crypt cells from the resected mucosa of 
patients with varied colon diseases: normal (n=16), colorectal cancer (CRC) (n = 17), 
Ulcerative colitis (UC) (n=13) and Crohn’s Diseases (CD) (n=10). The isolated cells were 




then cultured for 24 hours with 1 mM acetate, propionate or butyrate. While acetate and 
propionate had no significant effect on the secretion of IL-8 from the cells, butyrate 
significantly reduced the secretion of IL-8 in from the cells isolated from normal patients by 
20%, from CRC patients by 25%, from UC patients by 30% and from CD patients by 22% , 
when compared with cells that were not treated with butyrate. There was no significant 
difference across disease groups (Gibson & Rosella, 1995).  
In a different study by Gibson et al. they tested the effect of butyrate and TNFα alone and 
effect of butyrate after pre-incubating the cells with TNFα for 24h, on IL-8 secretion. They 
found that when the cells were incubated with 2mM butyrate alone or 10
-7
 M TNFα for 24h, 
IL-8 secretion more than doubled. But, when Caco-2 cells were pre-incubated with TNFα for 
24h, washed and then subsequently exposed to 2 mM butyrate for 24h, IL-8 secretion was 
suppressed by 34% from the basal levels (p = 0.03). 
The Caco-2 cell-line is an in vitro model that is used to determine the mechanisms and 
effects of various compounds on enterocytes or colonocytes. Caco-2 cells are a good model 
for IBD because they secrete high amounts of IL-8 when stimulated by inflammatory stimuli. 
The secretion of IL-8 is also dependent on the differentiation phase of the cells. Mariadason 
et al. determined the effect of butyrate treatment on secretion of IL-8 from Caco-2 cells at 
various phases of differentiation. In a 21-day growth period, they found that 5-days old cells 
secreted highest amount of IL-8 (1352% ± 166% above control), after being treated with 2 
mM butyrate for 72 hours. The secretion of IL-8 was high until the Caco-2 cells were 7 days 
old and this trend seemed to wear off by day 21. Huang et al. observed similar amount of 
secretion in 5-days old (pre-confluent) cells that were stimulated by IL-1β for 4 hours. They 
also observed a 6-fold decrease in the secretion of IL-8 in 18-days old (post-confluent) cells 




and in 5-days old (pre-confluent) cells that were treated with 2.5 mM sodium butyrate for 72 
hours, in comparison with untreated 5-days old cells (Huang et al., 1997). 
Through these studies, it can be concluded that exposure of inflamed Caco-2 cells to 2mM 
butyrate leads to a significant suppression of IL-8 concentration when compared with 
untreated, inflamed Caco-2 cells. 
OVERALL SUMMARY AND RATIONALE 
Increasing the intake of dietary fiber has been proven to reduce the risk of developing CD 
(Ananthakrishnan et al., 2013) and resistant starch has been shown to be protective against 
development of UC (Le Leu et al., 2013). These effects could be attributed to the anti-
inflammatory (Nishitani et al., 2013) or anit-oxidant (Scarminio et al., 2012) properties of 
dietary fiber.  
It has been proposed that dietary fiber imparts its protective effect against IBD through its 
fermentation byproduct – butyrate (Guilloteau et al., 2010). Several studies have been 
conducted to determine the mechanisms through which butyrate is protective against IBD 
(Hamer et al., 2010). However, these studies have limited implications because only the 
effect of butyrate has been studied alone. But other major fermentation products like acetate 
and propionate are also present in the colon (Cummings & Macfarlane, 1991). It is unknown 
if the effect of butyrate is affected by the presence of other short chain fatty acids. Hence, to 
fully understand the effect of butyrate against IBD, it is important to study its effect in the 
presence of other short chain fatty acids – acetate and propionate. 
Brouns et al. suggested that increasing the consumption of resistant starch would lead to an 
increase in the concentration of butyrate in the gut. Butyrate plays an important role in 
growth, proliferation and differentiation of gut epithelial cells. Butyrate has have anti-




inflammatory and anti-oxidative properties (Guilloteau et al., 2010). Butyrate enemas have 
been shown to be protective against the mucosal damage caused due to IBD (Hamer et al., 
2010; Luceri et al., 2016). Gibson and Rosella have showed that butyrate suppresses the 
secretion of the pro-inflammatory chemokine, IL-8. Since high concentrations of IL-8 has 
been proven to be a characteristic of UC and CD patients (Gibson & Rosella, 1995), 
suppression of secretion of IL-8 by butyrate may help in attenuating the effects of IBD. 
Hence, we hypothesized that an increased ratio of butyrate in the presence of physiological 
concentrations of acetate and propionate (as produced after fermentation of dietary fiber), 
would imporve the intestinal integrity and suppress IL-8 secretion in Caco-2 cells.  
RATIONALE FOR METHODS USED 
Caco-2 cells are human adeno-carcinoma cells that behave as colonocytes when grown in 
vitro for up to 7 days (Engle et al., 1998). To understand the protective effect of dietary fiber, 
it is important to study its effect on colonocytes and not enterocytes, because dietary fibers 
are highly fermented to SCFA in the colon (Cummings, 1981; Cummings & Macfarlane, 
1991). Caco-2 cells also secrete high concentrations of IL-8 when inflamed - similar to what 
occurs in IBD patients (Gibson & Rosella, 1995). Suppression of IL-8 by butyrate has also 
been observed in Caco-2 models (Huang et al., 1997; Mariadason et al., 2001). Due to all 
these characteristics, we selected to use Caco-2 cells as our model. 
Caco-2 cells were grown on Transwell plates such that it separated each well into two 
chambers – apical and basolateral. The apical chamber represents the apical surface of the 
intestinal epithelial cells and the basolateral chamber represents the basal and lateral surfaces 
of the intestinal epithelium. The apical surface of the epithelial cells faces towards the 




colonic lumen, where the gut microbes are present and the basolateral surface faces towards 









Fig 2: (Left) Cartoon representation of how an insert divides the well into two chambers – 
apical and basolateral. (Right) The apical and basolateral surfaces found in the intestinal 
epithelium as mimicked in the Transwell plates.  
 
To mimic the chronic inflammation observed in IBD patients, we used lipopolysaccharide 
(LPS) as an inflammatory stimulus on the apical side. LPS represents the microbial 
community found on the apical side of the epithelium. On the basolateral side, we used a 
mixture of pro-inflammatory cytokines tumor necrosis factor α (TNFα), interleukin-1β (IL-
1β) and interferon-γ (INF-γ) as used previously in our lab to inflame the cells (Qiang  et al., 
2011). 
The intestinal integrity of the cells was tested by the colorimetric method using Lucifer 
Yellow (LY). When the cells are highly permeable, the LY is easily transported from the 
apical chamber to the basolateral chamber. Hence, when high concentration of LY is 
measured in the basolateral chamber, it is concluded that the intestinal integrity of the cells is 









of Caco-2 cells (Kadota et al., 2013; Nemoto et al., 2015). Cell integrity was also measured 
by the quantifying the damage caused to the cells, by measuring the lactate dehydrogenase 
(LDH) activity. LDH is a soluble enzyme located in the cytosol. When the cell is damaged or 
lysed, LDH is released in the surrounding culture medium. LDH activity in the culture 
medium can therefore be used as an indicator of cell integrity (Haslam et al., 2000). Several 
other researchers have used this method to test for cell damage/cell permeability of Caco-2 
cells (Carrasco-Pozo et al., 2010; Chen et al., 2017). 
Hence, our objective was to determine the effect of increased ratio of butyrate in the presence 
of physiological concentrations of acetate and propionate on the intestinal integrity and IL-8 
secretion in inflamed and non-inflamed Caco-2 cells. 
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CHAPTER 2: EFFECT OF INCREASED RATIO OF BUTYRATE TO 
PHYSIOLOGICAL CONCENTRATIONS OF ACETATE AND PROPIONATE ON 
INTESTINAL INTEGRITY AND IL-8 SECRETION IN CACO-2 CELLS 
Nidhi Shah, Suzanne Hendrich 
Food Science and Human Nutrition, Iowa State University 
ABSTRACT 
 
Background: Chronic inflammation of the gut could be combated by increasing the 
consumption of dietary fiber which would lead to an increased butyrate production in the 
colon. Butyrate has been shown to improve intestinal integrity and suppress the secretion of 
pro-inflammatory cytokine, IL-8. 
Experimental Design: Caco-2 cells were grown to 90-100% confluence on Transwell plate 
inserts for 4 days, then inflammation was induced for 24h. The inflamed and non-inflamed 
Caco-2 cells were then exposed to: (i) 60 mM acetate (Ac): 10mM propionate (Pr): 10mM 
butyrate(Bu) (lower butyrate ratio) or (ii) 60 mM Ac: 10mM Pr: 20mM Bu (higher butyrate 
ratio)  for 0h, 12h or 24h. Intestinal integrity was measured by amount of Lucifer yellow 
transported from the apical to basolateral chamber of Transwell plates. IL-8 secretion was 
measured by ELISA and cell damage was measured by the lactate dehydrogenase 
cytotoxicity assay. 
Results: Cells that were inflamed significantly decreased the intestinal integrity (p=0.0094), 
increased the secretion of IL-8 (p<0.0001) and induced higher cell damage (p<0.0001) than 
non-inflamed Caco-2 cells, n=54. SCFA mix containing higher butyrate ratio (20mM) 
significantly reduced the intestinal integrity of inflamed cells (p=0.0238, n=27). Higher 
butyrate ratio did not affect the secretion of IL-8; but it led to greater cell-damage (p=0.0161, 




n=54). Prolonged exposure to SCFA improved intestinal integrity (p<0.0001), increased the 
secretion of IL-8 (p<0.0001) and led to greater cell damage (p<0.0001), n=36. Conclusion: 
Our hypothesis was disproved, but the important lesson to be learned is that the effect of 
butyrate in colonocyte models should be studied in the presence of other SCFA, to assure 
physiological relevance. 
Key words: inflammatory bowel disease, IBD, butyrate, IL-8, Caco-2, inflammation 
INTRODUCTION 
Inflammatory bowel diseases (IBD) are a global health problem. According to 
Centers for Disease Control and Prevention (CDC)
1
, 1 – 1.3 million people in USA, 2.5-3.3 
people in Europe and nearly 200,000 people in Canada suffer from IBD (Kaplan, 2015b). 
The direct health care cost in these three countries is nearly $13 billion (Kaplan, 2015b). Due 
to the influence of industrialization from Western civilizations, the incidence of IBD is on the 
rise in developing nations of Asia, South America and the Middle East. By 2025, the 
prevalence of IBD in the developing nations will match the current prevalence rate of the 
western civilizations (Molodecky et al., 2012; Kaplan, 2015b). 
There are two types of IBD. Chronic inflammation of the large intestine (colon and 
rectum) leads to development of Ulcerative Colitis (UC) and chronic inflammation of the 
digestive tract leads to development of Crohn’s disease (CD). IBD has been treated with 
pharmacological drugs like non-steroidal anti-inflammatory drugs (NSAIDs), mesalazine, 
sulfasalazine, aminosalicylic acid, TNF-inhibitors or COX-inhibitors. While these drugs are 
effective in alleviating the symptoms of IBD in several individuals, the effects could be 
short-term; the sufferers of IBD may develop side-effects to these drugs; or these drugs are 
not equally effective in all individuals suffering from IBD (Meyer et al., 2006; Paiotti et al., 




2012). Hence, there is a need to develop therapies that are effective in all individuals without 
causing the development of side-effects. This can be achieved through therapeutic dietary 
interventions.  
Increasing the consumption of dietary fiber (DF) among IBD patients is one of the 
tested dietary intervention strategies. Dietary fiber has been proven to impart anti-
inflammatory properties and alleviate some of the IBD symptoms in several animal studies 
(Bassaganya-Riera et al., 2011; Le Leu et al., 2013; Nishitani et al., 2013; Majumder et al., 
2017). The hypothesis is that by increasing the consumption of DF, the gut microbiota would 
receive more of it and they would ferment the DF to produce butyrate and other short chain 
fatty acids (SCFA).  
. Butyrate is the main energy source for colonocytes; promotes the expression of anti-
inflammatory cytokines and suppresses the expression of pro-inflammatory cytokines 
(Guilloteau et al., 2010). Moreover, butyrate enema studies in humans have shown that 
butyrate is anti-inflammatory and tends to reduce the symptoms related to UC (Hamer et al., 
2009; Hamer et al., 2010; Luceri et al., 2016). Similarly, treatment of induced-colitis with 
butyrate in mice (Vieira et al., 2012) and rats (D' Argenio et al., 2007) have shown similar 
alleviation properties of butyrate. Moreover, D’ Argeniao et al. also showed that butyrate 
treatment reduced the number and size of tumors against colitis induced colorectal cancer, in 
rats. The anti-inflammatory and anti-oxidative properties of butyrate make it an attractive 
form of treatment against UC. 
Gibson et al. determined that the colonic crypt cells obtained from UC and CD 
patients have increased concentration of pro-inflammatory cytokine IL-8, which can be 
suppressed by butyrate. Other researchers have found similar suppressive effect of butyrate 




against IL-8 (Huang et al., 1997; Pedersen et al., 2000; Lin et al., 2015; Pedersen, 2015). 
Hence, IL-8 is a good marker to test the effects of butyrate.  
Caco-2 cells are human adenocarcinoma cells, which when grown in the lab for seven 
days, retain the characteristics of colonocytes (Huang et al., 1997; Engle et al., 1998; 
Mariadason et al., 2001). This is important because the fermentation of dietary fiber occurs 
in the colon and the greatest amounts of SCFA are produced in the colon (Cummings, 1981; 
Cummings et al., 1987). Additionally, Caco-2 cells can be inflamed by exposing them to pro-
inflammatory cytokines like tumor necrosis factor α (TNFα), interleukin-1β (IL-1β) and 
interferon-γ (INFγ) (Qiang  et al., 2011). Hence, Caco-2 cells are a good model for ulcerative 
colitis and to determine the effect of SCFA on both – inflamed and non-inflamed cells.  
Most of the studies conducted so far have determined the effect of only one short 
chain fatty acid - butyrate on IL-8 (Gibson & Rosella, 1995; Mariadason et al., 1999; 
Mariadason et al., 2001). But physiologically, acetate and propionate are also present in high 
amounts in the colonic lumen (Cummings, 1981; Cummings et al., 1987). Hence, to make it 
physiologically relevant, we aimed to determine if an increased ratio of butyrate with respect 
to physiological concentrations of acetate and propionate would suppress the secretion of IL-
8 from inflamed and non-inflamed Caco-2 cells.  
At the time of designing this experiment, there were no published studies that 
determined the effect of butyrate on intestinal integrity in the presence of other SCFA. But 
recently, Chen et al. published a paper that determined the effect of exposing inflamed and 
non-inflamed cells to total SCFA concentration of 40 mM containing 5, 10, 20 or 50% 
butyrate for 48h on intestinal integrity. However, there are differences between the two 
studies. For this study, inflamed and non-inflamed Caco-2 cells were exposed to either  60 




mM acetate: 10mM propionate: 10mM butyrate or 60 mM acetate: 10mM propionate: 20mM 
butyrate SCFA mix for 24h, which is more physiologically relevant. To inflame the Caco-2 
cells Chen et al. exposed them to 10 µg/mL lipopolysaccharide (LPS) on the apical side of 
the Transwell plates and 50 ng/mL TNFα on the the basolateral side of the Transwell plates 
for 48h. In this study, the Caco-2 cells were exposed to 1 µg/mL LPS on apical side and a 
cocktail of 25 ng/mL IL-1β  , 50 ng/mL TNF-α and 50 ng/mL IFN-γ on the basolateral side 
of the Transwell plates for 24h. Due to these differences in the ratio of SCFA, time of 
exposure to SCFA, concentration and composition of the inflammatory stimulus and time of 
exposure to the inflammatory stimulus, the two studies are comparable but not same.  
Our hypothesis is that when inflamed Caco-2 cells are exposed to an increased ratio 
of butyrate to physiological concentrations of acetate and propionate (as produced after 
fermentation of dietary fiber), intestinal integrity is improved and IL-8 secretion is reduced. 
The aim of this study is to determine the effect of increased ratio of butyrate to physiological 
concentrations of acetate and propionate on intestinal integrity and suppression of IL-8 
secretion. 
MATERIALS AND METHODS 
Chemicals 
Dulbecco’s Modified Eagle’s Medium (DMEM), 0.5% trypsin - EDTA, antibiotic-
antimycotic, L-glutamine, HEPES and Hank’s Balanced Salt Solution (HBSS) were 
purchased from Life Technologies Corp. (Carlsbad, California). Interferon γ – (INFγ), Tumor 
Necrosis Factor α (TNF α), Interleukin – 1β (IL-1β) , lipopolysaccharide (LPS) and Lucifer 
yellow (LY), sodium acetate, sodium propionate and sodium butyrate were purchased from 




Fisher Scientific (Hanover Park, Illinois). The ELISA kit to determine the concentration of 
IL-8 was purchased from Qiagen (Valencia, California). 
Study design 
Colorectal carcinoma (Caco-2) cells were used to determine the effect of an increased 
butyrate concentration in a mixture of butyrate, acetate and propionate, on secretion of IL-8. 
To assure that Caco-2 cells retained the characteristics of a colorectal cell (Engle et al., 
1998), Caco-2 cells were grown for 3 days on inserts of a Transwell plate such that the 








Fig 1: Cartoon representation of how an insert divides the well into two chambers – apical 
and basolateral. 
 
On the fourth day, Lucifer Yellow transport experiment was conducted to determine the 
intestinal integrity of the Caco-2 cell monolayer formed on the inserts. On the fifth day, half 
of wells were inflamed for 24 hours, by exposing the Caco-2 cells to a cocktail of 
inflammatory stimuli. Following inflammation, the Caco-2 cells were exposed to two 
different ratios of acetate: propionate: butyrate (Ac : Pr : Bu) for 0h, 12h and 24h. The media 
was collected after each time point, to determine the concentration of IL-8 secreted by the 









group, there were three replicates and the entire experiment was conducted three times. 
Hence, n = 9 for each of the four experimental groups. 
Cell culture 
Caco-2 cells were purchased from American Type Culture Collection (ATCC) at 
passage number 17. Once received, Caco-2 cells were revived and further grown to 
confluence on 25 cm
2
 flasks. The cells were grown in Dulbecco’s Modified Eagle medium 
(DMEM) containing 10% fetal bovine serum (FBS), 10 mM HEPES buffer, 2 mM L-
glutamine and 1% antibiotic-antimycotic reagent. The cells were incubated at 37 ̊ C in an 
atmosphere of 5% CO2 (Hubatsch   et al., 2007).  
For the experiments, cells were grown on 75 cm
2 
flasks. Passage numbers 31-36 were 
used for the experiments. On day 1, the cells were seeded on 12mm polyester membrane 
inserts with pore size of 0.4 μm. These inserts were fitted in the chambers of a 12-well plate 




. The fitted inserts would divide the wells into two chambers – apical 
(AP) and basolateral (BA) as shown in figure 1. By day 3, the cells were ready for the 
experiment as they were 80% – 90% confluent (Borthakur    et al., 2008; Lecona    et al., 
2008). On day 4, Lucifer Yellow Transport Experiment was conducted to assess the 
permeability of Lucifer yellow from the AP chamber to the BA chamber. This experiment 
helped us determine the permeability of the cells. On day 5, DMEM containing an 
inflammatory stimuli composed of IL-1β (25 ng/mL), TNF-α (50 ng/mL) and IFN-γ (50 
ng/mL) was added to the BA chamber of half of all the wells, and  LPS (1 µg/mL) was added 
to both – AP and BA chambers of those wells. The other half of wells received only DMEM. 
After 24 hours, the media was replaced with media containing one of the two ratios of freshly 
prepared short chain fatty acid (SCFA) mixes: (1) 60 mM acetate: 10 mM propionate: 10 




mM butyrate (2) 60 mM acetate: 10 mM propionate: 20 mM butyrate. The medium was 
collected after 0, 12 or 24 hours of exposure to SCFA mixes from all wells. This medium 
was then analyzed using ELISA, to determine the concentration of secreted IL-8. In every 
experiment, three replicates were used for each of the experimental groups: Non-inflamed + 
SCFA Mix 1, Non-inflamed + SCFA Mix 2, Inflamed + SCFA Mix 1, Inflamed + SCFA Mix 
2. The entire experiment was conducted three times. Hence, n = 9 for each experimental 
group. 
Lucifer Yellow Transport Experiment 
Lucifer Yellow transport experiment was conducted on the fourth day of every 
experiment to determine the integrity of the barrier function of Caco-2 cells. To conduct the 
experiment, DMEM in the AP chamber was replaced with 100 µM Lucifer yellow (LY) in 
HBSS and only HBSS in the BA chamber.  After incubating the plates for one hour at 37 ̊ C, 
the solution from each chamber was collected separately. Absorbance of each sample was 
measured in duplicates, at 450 nm using the microplate reader (Biotek, Synergy2). Using the 
standard curve for LY, the absorbance values were then converted to concentration of LY 
present in each sample to determine the amount of LY that was transported from the AP 
chamber to the BA chamber (Qiang  et al., 2011).  
Determination of IL-8 concentration using ELISA 
On the fifth day of the experiment, the cells were exposed to inflammatory stimuli for 
24 hours, and then treated with SCFA for 0h, 12h or 24h. At the end of each time-point, the 
medium was collected from each of the AP and BA chambers and stored at -80 ̊ C until 
further analysis. Following the manufacturer’s protocol, the medium collected from AP 
chamber was analyzed using an enzyme-linked immunosorbent assay (ELISA) kit from 




Qiagen (Valencia, California), in duplicates. The amount of IL-8 secreted from Caco-2 cells 
was then calculated using a standard curve. 
Cell viability test 
The lactate dehydrogenase (LDH) cytotoxicity assay kit was purchased from Cayman 
Chemical, Michigan. The kit was used to measure the LDH activity as an indicator of cell 
death, as suggested in the protocol. Supernatant was collected twice, from the plates during 
the experiment- post-inflammation and post SCFA exposure. 100µl of the supernatant from 
each well was transferred to a 96-well plate and then 100µl of the LDH reaction solution 
(prepared as per the protocol) was added. The plates were gently shaken on an orbital shaker 
at 37 ̊ C for 30 minutes. Then absorbance was read at 490 nm using a microplate reader 
(Biotek, Synergy2).The absorbance values were compared between treatments. 
Statistical Analysis 
The data was analyzed using the ANOVA and MIXED models to determine the 
statistical significance of the differences between the treatments using SAS 9.4 software. P-
values < 0.05 were considered to be significant.  
RESULTS 
Effect of inflammation, SCFA ratio and time on intestinal integrity 
LY transport experiment was conducted twice – before inflaming the cells (before 
inflammation) and after SCFA-exposure. When the concentrations of basolateral LY of all 
the wells were combined (12 wells for each time point X 3 time points (0h,12h,24h) X 3 
repetitions of the experiment), the average concentration of basolateral LY  before 
inflammation was 3.08 ± 2.41 mM (n=108) and after SCFA exposure was 2.44 ± 1.94 mM 
(n=108). One way ANOVA showed that the average basolateral concentration of LY after 




SCFA-exposure was significantly lower than the average basolateral concentration of LY 
before inflammation (p=0.0327, n=108), indicating an improvement in the intestinal integrity 
(Fig 2). 
 
Fig 2: Basolateral concentration of Lucifer Yellow before inflammation and after SCFA-
exposure for designated amount of times (0h, 12h, 24h). p = 0.0327, n = 108. Different letters 
indicate a significant difference at p<0.05 (Tukey comparison). 
 
In order to determine how the experimental treatments would have contributed 
towards improving the intestinal integrity, the basolateral concentrations of LY after SCFA-
exposure were analyzed by 3-way ANOVA with respect to the three independent variables – 
inflammation, SCFA ratio and time and interactions between them. Statistical analysis 
showed that the average basolateral concentration of LY of inflamed cells was significantly 
greater than the average basolateral concentration of LY of non-inflamed cells (p=0.0094, 
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Fig 3: Basolateral concentration of Lucifer Yellow of all inflamed and non-inflamed cells, 
irrespective of the SCFA ratio and the time of exposure to SCFA mix. Different letters 
indicate that the treatments were significantly different from one another. p = 0.0094, n = 54. 
 
Post-SCFA exposure, 3-way ANOVA analysis showed that the average basolateral 
concentration of LY exposed to the SCFA ratio containing higher amount of butyrate (20 
mM) was greater than the average basolateral concentration of LY exposed to the SCFA ratio 
containing lower amount of butyrate (10 mM), but it was not statistically significant 
(p=0.1020, n=54). This indicates that the increased amount of butyrate did not have any 

















































p = 0.0094, n = 54 






Fig 4: Basolateral concentration of Lucifer Yellow of all the cells exposed to SCFA ratio 
containing lower butyrate (10mM Bu) or higher butyrate (20mM Bu), irrespective of 
inflammation and the time of exposure to specific SCFA mix. Different letters indicate that 
the treatments were significantly different from one another. p=0.1020, n = 54. 
 
Although there was no significant effect of SCFA ratios on the basolateral concentration of 
LY, there was an interaction effect between inflammation and the ratio of SCFA mix used, 
on the basolateral concentration of LY (p =0.0238, n=27). The average basolateral 
concentration of LY of inflamed cells that were exposed to the SCFA ratio containing higher 
(20mM)  concentration of butyrate was significantly greater than that of inflamed cells that 
were exposed to the SCFA ratio containing lower (10mM) concentration of butyrate (p = 
0.0387, n = 27), indicating that the intestinal integrity of the cells was weakened (Fig 5). The 
basolateral concentration of LY of the inflamed cells exposed to the SCFA ratio containing 
higher (20mM) butyrate was significantly greater than that of non-inflamed cells exposed to 
the SCFA ratio containing higher (20mM) butyrate (p=0.0103, n=27), indicating that the 
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Fig 5: Basolateral concentration of Lucifer Yellow of all the inflamed and non-inflamed cells 
that were exposed to SCFA ratio containing lower amount of butyrate (10 mM Bu) or higher 
amount of butyrate (20 mM Bu), irrespective of the time of exposure to SCFA. This graph 
shows the interaction effect between inflammation and SCFA mix ratio on basolateral 
concentration of LY. Different letters indicate that the treatments were significantly different 
from one another. p=0.0238, n = 27. 
 
 The basolateral concentration of LY of inflamed and non-inflamed cells that were 
treated with SCFA for 12h or 24h, was significantly lesser (p<0.0001, n=36) than that of 
inflamed and non-inflamed cells that were treated with SCFA for 0h. However, there was no 
significant difference between the cells that were treated with SCFA for 12h and the cells 
that were treated with SCFA for 24h. These results indicate that the intestinal integrity of the 
cells improved when they were exposed to SCFA for a longer time (Fig 6). There was no 
significant interaction effect between time and inflammation or time and SCFA ratio on the 
basolateral concentration of LY. Also there was no significant interaction effect between 
























































Fig 6: Basolateral concentration of Lucifer Yellow of all the cells exposed to SCFA for 
specific time-points, irrespective of inflammation and the SCFA ratio they were exposed to. 
Different letters indicate that the treatments were significantly different from one another. 
p<0.0001, n = 36. 
 
Effect of inflammation, SCFA ratio and time on IL-8 secretion 
In order to determine the effect of the independent variables (inflammation, SCFA 
ratio and time) and interactions between them on the secretion of IL-8, the concentrations of 
IL-8 determined by ELISA were analyzed using 3-way ANOVA. Statistical analyses showed 
that cells that were inflamed, secreted significantly greater amount of IL-8 (p<0.0001, n=54) 
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Fig 7: Concentration of IL-8 secreted from all inflamed and non-inflamed cells, irrespective 
of the SCFA ratio used and the time of exposure to SCFA mix. Different letters indicate that 
the treatments were significantly different from one another. p<0.0001, n = 54. 
 
Post-SCFA exposure, 3-way ANOVA analysis showed that the cells that were 
exposed to SCFA mix containing higher (20mM) amount of butyrate slightly increased the 
secretion of IL-8, but was not significantly different (p=0.1162, n=54) when compared with 
the cells that were exposed to SCFA mix containing  lower (10mM) amount of butyrate. This 
indicates that the ratio of SCFA mixes used did not have any significant effect on secretion of 














































p < 0.0001, n = 54 






Fig 8: Concentration of IL-8 secreted from all the cells that were exposed to SCFA mix 
containing lower amount of butyrate (10mM Bu) or higher amount of butyrate (20mM Bu), 
irrespective of inflammation and the time of exposure to specific SCFA mixes. Different 
letters indicate that the treatments were significantly different from one another. p=0.1162, 
n=54. 
 
Post-SCFA exposure, the time for which the cells were exposed to specific SCFA 
ratios had a significant effect (p<0.0001, n=36) on the secretion of IL-8; and, the secretion of 
IL-8 increased with an increase in the amount of time for which the cells were exposed to the 













































     p = 0.1162, n = 54 






Fig 9: Concentration of IL-8 secreted from all the cells exposed to SCFA for specific time-
points, irrespective of inflammation and the SCFA mix ratio they were exposed to. Different 
letters indicate that the treatments were significantly different from one another. p<0.0001, 
n=36. 
 
Statistical analysis showed that there was a significant 2-way interaction effect 
between inflammation and time on the secretion of IL-8 (figure not shown). However, there 
were no significant 2-way interaction effects between inflammation and the SCFA ratio or 
time and SCFA ratio, on the secretion of IL-8. Also there was no significant 3-way 
interaction effect between inflammation, SCFA ratio and time, on the secretion of IL-8. 
Effect of inflammation, SCFA ratio and time on LDH activity 
LDH activity of the cells from each well was measured from the medium collected 
after inflammation and after SCFA exposure, using the LDH cytotoxicity assay.  Post-
inflammation, one-way ANOVA showed that the LDH activity of inflamed cells was 
significantly higher than the LDH activity of non-inflamed cells (p<0.0001, n=54), indicating 






































  p < 0.0001, n =36 






Fig 10: Post-inflammation, activity of lactate dehydrogenase of inflamed and non-inflamed 
cells. Different letters indicate that the treatments were significantly different from one 
another. p<0.0001, n = 54. 
 
Post-SCFA exposure, 3-way ANOVA analysis showed that the LDH activity of the 
cells that were exposed to SCFA mix containing higher (20mM) amount of butyrate was 
significantly greater (p=0.0161, n=54) than the LDH activity of the cells that were exposed to 
SCFA mix containing lower (10mM) butyrate, indicating that the cells that were exposed to 
higher butyrate containing SCFA mix were more damaged than the cells that were exposed to 
































p < 0.0001, n = 54 






Fig 11: Post-SCFA exposure, activity of lactate dehydrogenase of the cells that were exposed 
to SCFA mix containing lower amount of butyrate (10 mM Buor higher amount of butyrate 
(20 mM Bu), irrespective of inflammation and the time of exposure to specific SCFA mixes. 
Different letters indicate that the treatments were significantly different from one another. 
p=0.0161, n=54. 
 
Post-SCFA exposure, the LDH activity significantly increased with increased time of 
exposure to SCFA (p<0.0001, n=36). This indicates that the cell damage increased with an 
increase in the amount of time the cells were exposed to SCFA mixes (Fig 12). All the 
pairwise interactions between inflammation, SCFA ratio and time also had a significant 



































p = 0.0161, n = 54 






Fig 12: Post SCFA exposure, activity of lactate dehydrogenase of cells that were exposed to 
SCFA mixes for specific amount of times, irrespective of inflammation and SCFA ratio they 
were exposed to. Different letters indicate that the treatments were significantly different 
from one another. p < 0.0001, n=36. 
 
DISCUSSION 
Transfer of Lucifer Yellow from the apical chamber to the basolateral chamber has 
been measured as a marker to determine intestinal integrity in Caco-2 cells by several 
researchers (Kadota et al., 2013; Nemoto et al., 2015). According to this study, inflammation 
compromised the intestinal integrity of Caco-2 cells, as measured by the transfer of the 
permeability marker - Lucifer yellow, which was expected. Research has shown that TNF-α, 
IL-1β and INF-γ decrease the intestinal integrity and make them more permeable (Ma et al., 
2004; Beaurepaire et al., 2009; Pedersen, 2015).  But in this study, the time of exposure to 
SCFA, tended to improve the intestinal integrity of the cells between 0h to 12h and 0h to 
24h, but not between 12h to 24h (Fig 6). While there was no significant effect of the ratio of 
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intestinal integrity of the cells, in this study. Chen et al. saw a similar increase in the 
intestinal integrity of Caco-2 cells as measured by trans-epithelial electrical resistance 
(TEER), when they were exposed to SCFA over 48h. Moreover, they found that the TEER 
values were significantly correlated to total SCFA concentration (r = 0.923, p = 0.009), 
acetate (r = 0.953, p = 0.003), and butyrate (r = 0.813, p = 0.049). They found  that when 
Caco-2 cells were exposed to the SCFA ratios: 24mM (60%) acetate: 8mM (20%) 
propionate: 8mM (20%) butyrate or  15mM (37.5%) acetate: 5mM (12.5%) propionate: 
20mM (50%) butyrate, the TEER values at 48h were increased by 1.4-fold and 1.7-fold, 
respectively (Chen et al., 2017). Contrary to our hypothesis, the results of our study indicated 
that inflamed cells that were exposed to the ratio of 60 mM Ac: 10mM Pr: 20mM Bu (higher 
butyrate) increased the transport of Lucifer Yellow from the apical side to the basolateral 
side. This would be possible only when the Caco-2 cell monolayer was more permeable due 
to compromised intestinal integrity. These results in contrast with Chen et al. suggest that the 
ratio and concentration of SCFA used may influence the intestinal integrity of the cells. The 
other thing to note is that butyrate may act differently in the presence or absence of SCFA. 
Peng et al. found that when Caco-2 cells were exposed to 8mM butyrate, the TEER values 
were not significantly different from that of Caco-2 cells not treated with butyrate for 24h. 
But by 48h the TEER values of Caco-2 cells exposed to 8 mM butyrate was 1.25-fold lower 
than the TEER values of untreated Caco-2 cells and it kept declining until it was lower by 8-
fold at 96h. Whereas the TEER values of Caco-2 cells that were exposed to 2mM butyrate 
for 72 hours, were 1.5-fold significantly higher than that of untreated Caco-2 cells at 48h and 
they remained steady until 96h (Peng et al., 2007).  These results are in contrast with that of 
Chen et al. While Peng et al. reported that cells treated with 8 mM butyrate had lower TEER 




values by 48h, Cheng et al. observed an improvement in the TEER values in cells treated 
with 8mM butyrate containing SCFA mix for 48h. These differences in the TEER values 
may be due to the presence of other SCFA. Hence, it is crucial that future projects that aim to 
study the effect of butyrate on intestinal integrity, be conducted in the presence of other 
SCFA. 
Similar to the LY results, inflammation and the time of exposure to SCFA increased 
the secretion of IL-8 but as opposed to our hypothesis, the ratio of SCFA used did not have 
any effect on the secretion of IL-8. These results are different from that of previous 
researchers. Huang et al. found that when 5-days old Caco-2 cells that were inflamed by 
exposure to 5 ng/ml IL-1β for 4hours, they secreted high concentrations of IL-8. When these 
inflamed cells were then treated with 2.5 mM sodium butyrate for 72 hours, the IL-8 
secretion was reduced by 6-fold (Huang et al., 1997). Gibson et al. observed that when Caco-
2 cells were exposed to 10 µM TNF-α for 24h, the secretion of IL-8 doubled in comparison 
with untreated Caco-2 cells. IL-8 secretion nearly doubled even when the Caco-2 cells were 
exposed to 2mM butyrate for 24h. However, when Caco-2 cells were pre-treated with 10 µM 
TNF-α, washed and then exposed to 2 mM butyrate, IL-8 secretion decreased by 34% below 
basal levels (p = 0.03). These differences could probably be because these researchers used 
only butyrate as opposed to the mixture of acetate, propionate and butyrate used for this 
study. The difference in our results from that of previous researchers could also be attributed 
to the concentration of butyrate and the inflammatory stimuli used. We used the specific 
SCFA ratios to mimic the physiological concentrations found in a human being (Cummings, 
1981; Cummings et al., 1987). To be able to mimic the aspect of consuming higher-fiber 
diet, we decided to double the concentration of butyrate in the SCFA mix, because 




fermentation of dietary fiber leads to increased production of butyrate. The inflammatory 
stimulus that we used was a mixture of TNFα, IL-1β and INF-γ for basolateral side and LPS 
for the apical side, to represent acute inflammatory reactions and mimic chronic and severe 
inflammatory bowel disease (Chavez et al., 1999; Qiang  et al., 2011). 
The LDH activity results also showed that inflammation, higher butyrate containing 
SCFA mix and increasing amount of time of exposure to SCFA increased the LDH activity, 
indicating that these factors led to more cell-damage. LDH cytotoxicity test is a measurement 
of the amount of cytosolic lactate dehydrogenase in the supernatant that is released from cells 
that are damaged. This assay has been used by several researchers as a test of cytotoxicity or 
cell viability (Carrasco-Pozo et al., 2010; Kadota et al., 2013; Pedersen, 2015). Huang et al. 
did not report the results but mentioned that Caco-2 cells treated with 20 mM butyrate led to 
increased toxicity. Peng et al. also found that Caco-2 cells exposed to 8 mM butyrate for 72 
hours, led to a 5-fold increase in the number of cells that were floating (indicator of dead 
cells) in comparison with Caco-2 cells that were not treated with butyrate. They did not find 
a similar apoptosis rate in cells that were exposed to 2 mM butyrate for 72 hours (Peng et al., 
2007). These results suggest that the concentration of butyrate used in the mixture or the 
presence of other SCFA could have influenced the amount of cell damage incurred by the 
Caco-2 cells.  
CONCLUSION 
Although our hypothesis - when inflamed Caco-2 cells are exposed to an increased 
ratio of butyrate to physiological concentrations of acetate and propionate (as produced after 
fermentation of dietary fiber), intestinal integrity is improved and IL-8 secretion is reduced 
was disproved, several lessons can be learned from this study. Firstly, butyrate may behave 




differently in the presence of other SCFA. So for future studies it is important to study the 
effects of the combination of SCFA as opposed to butyrate alone. Secondly, the ratio and 
concentration of SCFA used should be carefully selected such that it is physiologically 
relevant and not highly toxic to cells in vitro. This would be extremely important while 
simulating the effects of consumption of high-fiber diets that would lead to increased 
butyrate concentration in the colon. Future work is required to determine the concentrations 
of SCFA and change in the concentration of SCFA in the colon due to high-fiber 
consumption and the effect of these changes on the intestinal epithelial cells. 
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 CHAPTER 3: GENERAL CONCLUSIONS 
Several studies have been conducted to determine the effect of dietary fiber and short chain 
fatty acids on general health and in diseased states. While there is evidence from 
epidemiological studies regarding the inverse relationship between dietary fiber intake and 
the risk of developing inflammatory bowel diseases, more research needs to be done to prove 
if dietary fiber acts as a preventative measure or a therapeutic one. Also, one should note that 
there are different types of dietary fibers that have different gastrointestinal fate. Hence, the 
protective or reparative effects of dietary fibers need to be characterized by its type.  
An increased concentration of butyrate due to higher fermentation of dietary fiber is one of 
the mechanisms that has been attributed towards it’s the protective effect. Several studies 
have been conducted to determine the effect of butyrate on intestinal epithelial cell in vivo 
and in vivo. However, it is important to note that the colonic lumen contains other byproducts 
of microbial fermentation that may impact the effect of butyrate. Hence, future studies should 
be mindful about determining the effect of butyrate in the presence of other luminal products 
like short chain fatty acids like acetate and propionate which are also to be found at high 
concentrations in the lumen. Moreover, the ratio and concentrations of these SCFA should be 
carefully selected such that it is physiologically relevant and not highly toxic to cells in vitro. 
This would be extremely important for in vitro studies that would like to simulate the effects 
of consumption of high-fiber diets that leads to an increase butyrate concentration in the 
colon.  
Future work is required to determine the in vivo concentrations of SCFA and change in them 
due to high-fiber consumption and the effect of these changes on the intestinal epithelial cells 
in healthy and diseased states. 
